Locus Pharmaceuticals, Inc. has entered into a research agreement with Ono Pharmaceutical Co., Ltd. to apply its proprietary computational technologies, and capabilities in chemistry, biology and crystallography to develop IND-directed preclinical drug candidates for Ono. The molecular target is a protein kinase selected by Ono. Protein kinases function as control switches for many biochemical pathways inside cells and are of particular interest as targets for the development of novel therapeuti...